Mitsubishi Tanabe Pharma Corp - Company Profile
Powered by 
All the data and insights you need on Mitsubishi Tanabe Pharma Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Mitsubishi Tanabe Pharma Corp Strategy Report
- Understand Mitsubishi Tanabe Pharma Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures, and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system (CNS) disorders, and others. It also develops vaccines for preventing various infectious diseases. Mitsubishi Tanabe also offers major products for skin conditions and digestive medicines. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It has subsidiaries in Asia, Europe, and North America. Mitsubishi Tanabe is headquartered in Osaka, Japan.
Headquarters
Japan
Address
3-2-10, Dosho-machi, Chuo-ku, Osaka, 541-8505
Website
www.mt-pharma.co.jp
Telephone
81 6 62055085
No of Employees
6,697
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$3.4B
Mitsubishi Tanabe Pharma Corp premium industry data and analytics
Products and Services
| Products |
|---|
| Autoimmune Diseases: |
| Stelera |
| Simponi (golimumab) - Rheumatoid Arthritis |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In April, the company received an orphan drug designation from the US Food and Drug Administration (FDA) for RADICAVA ORS(edaravone) for treatment of amyotrophic lateral sclerosis (ALS). |
| 2024 | Regulatory Approval | In March, the company received approval for an additional dosage form of orally disintegrating tablets for SGLT2 inhibitor CANAGLU Tablets 100 mg. inhibitor CANAGLU Tablets 100 mg. |
| 2024 | New Products/Services | In February, the company launched Radicava as an intravenous treatment for amyotrophic lateral sclerosis. |
Competitor Comparison
| Key Parameters | Mitsubishi Tanabe Pharma Corp | Astellas Pharma Inc | Daiichi Sankyo Co Ltd | Chugai Pharmaceutical Co Ltd | Taisho Pharmaceutical Holdings Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Osaka | Chuo-Ku | Chuo-Ku | Chuo-Ku | Toshima-Ku |
| State/Province | Osaka | Tokyo | Tokyo | Tokyo | Tokyo |
| No. of Employees | 6,697 | 14,484 | 17,435 | 7,771 | 8,784 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Tsujimuaa Akihiro | Director | Non Executive Board | - | - |
| Ueno Hiroaki | Director | Non Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward